| Literature DB >> 35501766 |
P Correa-Burrows1, R Burrows2, C Albala2, F A Court3,4,5, F Salech4,6, G Sanhueza7, C Gonzalez-Billault2,4,5,6,8.
Abstract
BACKGROUND: Aging is characterized by a progressive loss of capacities linked to fundamental alterations/damage in multiple cellular and molecular pathways. It is the most significant risk factor for all non-communicable diseases (NCDs). Another contributing factor to the rise in NCDs is obesity. It has been suggested that obesity not only accelerates the onset of metabolic imbalances but also decreases lifespan and impacts cellular and molecular processes in a manner similar to aging. Obesity might accelerate the pace of aging. Guided by a lifecourse approach, we will explore how exposure to obesity in critical developmental stages disrupt homeostatic resilience mechanisms that preserve physiological integrity, inducing an early expression of aging phenotypes. Also, we will determine whether exposure to early psychosocial adversity influences vulnerability to obesity as a risk factor for accelerated aging.Entities:
Keywords: Aging; Dysbiosis; Early-onset cardiometabolic risk; Epigentic age; Obesity; Resilience; Sarcopenia
Mesh:
Substances:
Year: 2022 PMID: 35501766 PMCID: PMC9063300 DOI: 10.1186/s12877-022-03032-4
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 4.070
Fig. 1The Santiago longitudinal study, 1992–2022
Fig. 2Obesity and cardiometabolic risk from adolescence to emerging adulthood in the Santiago Longitudinal Study (n = 630). The subset includes participants with repeated measures at 16y and 23y. Exact McNemar’s test: *Significant at P ≤ 0.05. **Significant at P ≤ 0.01. ***Significant at P ≤ 0.001. Obesity defined as BMI ≥ 30 kg/m2. Insulin Resistance defined as HOMA-IR > 2.6. Metabolic Syndrome defined according to the AHA/IDF joint criteria. LGS Inflammation defined as hs-C reactive protein ≥ 3 mg/L according to CDC/AHA
Available Data in the Santiago Longitudinal Study (29y assessment is ongoing, aiming to relate exposure to early psychosocial adversity to cardiometabolic risk in adulthood)
| Type of Measure | Method/instrument | Infancy | Childhood | Adolescence | 23y assessment | 29y assessment | |
|---|---|---|---|---|---|---|---|
| Epidemiology | Demographics | Age, sex, residence area | X | X | X | X | X |
| Socioeconomic | Income, economic responsibilities, financial access, human & social capital, future income expectations & worries, SES change. | X | X | X | X | X | |
| Individual risk (I) | Behavior problems, mental health, emotional regulation, stress, dating violence. | X | X | X | X | X | |
| Individual risk (II) | child abuse and neglect, intrafamily violence, having a parent with untreated mental illness, financial distress, feeling unsecure | X | X | X | X | X | |
| Individual risk (III) | Tobacco, alcohol, drug use. | X | X | X | |||
| Individual functioning | Work, relationship, living independently, social network, life events. | X | X | ||||
| Education | Academic record, high school completion, college exams, higher education | X | X | X | |||
| Medical history | Acute, chronic, and mental disorders. Records of current and past medication. | X | X | X | |||
| Family medical history (I) | T2D, stroke, myocardial infarction, HTA, dyslipidemia | X | X | X | |||
| Family medical history (II) | Dementia/Alzheimer’s | X | |||||
| Diet (I) | Breastfeeding (total and exclusive) | X | |||||
| Diet (II) | Food-frequency data about food and beverages, 24H recall | X | X | X | |||
| Physical activity (I) | Exercise, active commuting, sedentary behavior | X | X | X | |||
| Physical activity (II) | Actigraphic recording | X | X | ||||
| Sleep | Pittsburgh Sleep Quality Index, Munich Chronotype Questionnaire, Epworth Sleepiness Scale | X | X | ||||
| Clinical | Anthropometry (I) | Height, weight, BMI, BMI (Z score) | X | X | X | X | X |
| Anthropometry (II) | Waist circumference, WtHR, WHR | X | X | X | |||
| Anthropometry (III) | Fat mass, fat-free mass, fat distribution (DXA) | X | X | ||||
| Cardiometabolic (I) | Blood pressure | X | X | X | |||
| Cardiometabolic (II) | Carotid intima thickness, pulse wave velocity. | X | X | ||||
| Bone density | BMD, BMDz, BMD, T score, BMC (DXA) | X | X | ||||
| Laboratory | Hematology | Full blood count, hematocrit, hemoglobin, platelets, white cell differentials | X | X | X | X | |
| Liver function | Liver ultrasound, serum AST, ALT, HCV antibody and HBsAg | X | |||||
| Lipid profile | Total Chol, HDL-Chol, TG, LDL, VLDL | X | X | X | |||
| Glucose control | Glucose, insulin, HOMA-IR, HOMA-β, HOMA-S, Disposition Index | X | X | X | |||
| Inflammatory markers (I) | hs-CRP | X | X | X | |||
| Inflammatory markers (II) | TNFα | X | |||||
| Appetite hormones | Leptin, ghrelin, adiponectin, orexin A | X | X | X | |||
| Other | Stress hormones | Cortisol (blood, saliva and hair) | X | ||||
| Bio specimens | Extracted DNA | X | |||||
| Bio specimens | Blood, biofluids and derivatives | X | X | X | |||
| Bio specimens | PBMC | X |